TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05681780

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating Lymphocytes (TIL)
Description: Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (Opdivo®), 360 mg, IV infusion every 3 weeks prior to TIL infusion, and then after TIL infusion 480 mg ever 4 weeks for up to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered on days -7 and -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will then be infused per institutional standard on Days -7 to -3.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating Lymphocyte Therapy
Description: On day 0, all patients will receive a dose infusion TIL cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL2)
Description: Participants will receive IL-2 for up to 6 doses, based on participants tolerance and investigator judgement. This will be given after the infusion of the T-cells.
Study: NCT05855135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTIMIZER® Integra CCM-D System (Treatment Arm)
Description: The CCM-D System is an implantable cardiac device system that combines cardiac contractility modulation and implantable cardioverter defibrillator (ICD) modules into one device. CCM-D is also known as a Cardiac Contractility Modulation - Defibrillator. All 300 subjects will be implanted with the CCM-D System and followed for a period of at least two years.
Study: NCT06538597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-compassion intervention (Self-Compassion for Healthcare Communities course)
Description: An online 6-week mindful self-compassion course with weekly sessions.
Study: NCT05269966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection Brolucizumab
Description: Single-chain antibody fragment (scFv)~Brolucizumab 6 mg was administered by Intravitreal (IVT) injection as per the Prescribing information (PI) and in line with the treating physician's clinical judgement. Patients received loading doses of brolucizumab at Day 0/Visit 1, Week 4/Visit 2 and Week 8/Visit 3. After the loading doses, at Week 16, disease activity assessment (DAA) were performed based on Best Corrected Visual Acuity (BCVA) and Optical Coherence Tomography (OCT) to assess whether the patient required q8w or q12w dosing.
Study: NCT06204809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGN-EDODM1 for infusion
Description: Single dose of PGN-EDODM1 by intravenous (IV) infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IV infusion
Study: NCT06444074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Activation through Conversations (PACT) Program
Description: Participants in the intervention arm will undergo a 3-month long health coaching program where a care coach will review a participant's health parameters and current self-care behaviours, identify health motivators and set goals for improving their diabetes, as well as fortnightly support through text or phone call.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Routine Chronic Disease care
Study: NCT06523010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Talocrural Joint Manipulation
Description: This technique, aiming to increase ankle dorsiflexion and mechanoreceptor activation, is based on the application of high velocity low amplitude traction to the joint.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Talocrural Joint Manipulation
Description: This intervention is a classic method used to evaluate the effect of talocrural joint manipulation.
Study: NCT05983952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD38 antibody Injection
Description: intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment.
Study: NCT04754997

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional exercise training
Description: The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. The lower extremity range of motion exercise and strengthening exercises will be applied on the mat 10 repetition. The number of repetitions and type of exercises will be changed every 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific exercise training
Description: The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. Exercise training consists of lower extremity closed kinetic chain exercises and core exercises. The type of exercise changes every 3 weeks.
Study: NCT06131450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M07D1
Description: Administration by intravenous infusion
Study: NCT05833126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
Description: Drug: Oxaliplatin, calcium folinate, 5-FU, Atezolizumab and bevacizumab Procedure: HAIC
Study: NCT06355661

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ParActin®: 300 mg + MCC: 100 mg (± 10%) per Capsule
Description: Two capsules/day (One capsule to be taken 30 minutes before breakfast \& one capsule to be taken 30 minutes before dinner)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MCC: 400 mg (± 10%) per Capsule
Description: Two capsules/day (One capsule to be taken 30 minutes before breakfast \& one capsule to be taken 30 minutes before dinner)
Study: NCT05756881

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cosmetic product
Description: Apply on the face twice a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cosmetic product
Description: Apply on the face twice a day
Study: NCT05434455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIPC induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion
Description: RIPC was induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion on the upper arm. By using blood pressure cuff inflation, patients in the RIPC group were exposed to a pressure 50 mmHg higher than the systolic radial artery pressure baseline.
Study: NCT05052853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDAE
Description: Use of an NMDA enhancer for the treatment of prodromal schizophrenia .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cap
Description: Use of placebo as a comparator
Study: NCT06524986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-efficacy promoting program using computer game
Description: The self-efficacy promotion program, inspired by Bandura's principles (1997, 2001) and employing computer games, extends across 5 weeks with 30-minute sessions conducted 10 minutes. Activities include: 1) Enactive Mastery Experiences 2) Modeling 3) Verbal Persuasion 4) Physiological and Affective States Assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard nursing care
Description: The control group received standard nursing care, which included providing dietary recommendations for pediatric patients. The recommended daily intake consisted of 0.8 grams of protein per kilogram of the child's weight, low-sodium foods, and low-fat options. This personalized guidance was communicated through informational brochures.
Study: NCT05337865

Intervention type: OTHER
Intervention: Aerobic exercise test.
Description: Aerobic exercise test at a treadmill.

Intervention type: OTHER
Intervention: Aerobic exercise test.
Description: Aerobic exercise test at a treadmill.

Intervention type: OTHER
Intervention: Aerobic exercise test.
Description: Aerobic exercise test at a treadmill.
Study: NCT05668897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG171
Description: This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG171
Description: This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG171
Description: This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of GST-HG171
Description: This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of GST-HG171
Description: This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
Study: NCT05863819

Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered in this study.
Study: NCT05801003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predilation with cutting balloon.
Description: PCI will be performed under OCT guidance. Predilation of the lesion will be done with cutting balloon.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Predilation with conventional balloon
Description: PCI will be performed under OCT guidance. Predilation of the lesion will be done with conventional balloon (semi-compliant or non-compliant)
Study: NCT06533085

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block by surgeon
Description: Three groups were evaluated in the study. All three groups underwent intraoperative PCI.~Group 1 (Adductor canal block by surgeon) Group 2 (Adductor canal block by anesthesiology specialist ) Group 3 (Control group)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block by surgeon
Description: Three groups were evaluated in the study. All three groups underwent intraoperative PCI.~Group 1 (Adductor canal block by surgeon) Group 2 (Adductor canal block by anesthesiology specialist ) Group 3 (Control group)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block by surgeon
Description: Three groups were evaluated in the study. All three groups underwent intraoperative PCI.~Group 1 (Adductor canal block by surgeon) Group 2 (Adductor canal block by anesthesiology specialist ) Group 3 (Control group)
Study: NCT05172050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Raloxifene was administered as 60 mg hard gelatine capsule(s) once a day. Starting from day 2 of treatment: one single capsule (plus one of placebo to guarantee the blinding) containing 60 mg raloxifene was administered in Group 1, and 2 capsules 60 mg each for a total of 120 mg in Group 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Raloxifene was administered as 60 mg hard gelatine capsule(s) once a day. Starting from day 2 of treatment: one single capsule (plus one of placebo to guarantee the blinding) containing 60 mg raloxifene was administered in Group 1, and 2 capsules 60 mg each for a total of 120 mg in Group 2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered orally once a day as 2 capsules (for maintaining the blinding design)
Study: NCT06487104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrachPhone HME
Description: Use of TrachPhone HME for humidification of inhaled air in tracheostomized patients.~The TrachPhone HME is an HME specifically designed for tracheostomy patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TrachPhone HME
Description: Use of TrachPhone HME for humidification of inhaled air in tracheostomized patients.~The TrachPhone HME is an HME specifically designed for tracheostomy patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External Humidifier (Usual Care)
Description: Usual care routines using an External Humidifier for humidification of inhaled air in tracheostomized patients.
Study: NCT06215885

Intervention type: DIAGNOSTIC_TEST
Intervention: Mass spectrometry-based proteomics
Description: Detecting genomic and proteomic information

Intervention type: DIAGNOSTIC_TEST
Intervention: Mass spectrometry-based proteomics
Description: Detecting genomic and proteomic information
Study: NCT05922501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: An IgG1-derived monoclonal antibody that targets CD38 proteins, administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: An antibody-drug conjugate that is the combination of an antibody targeting BCMA and a drug, administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: An immunomodulatory agent, capsule taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: A glucocorticoid which is a substance that stops inflammation cause by immune system disorders, tablet taken orally.
Study: NCT05177887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traumacel PULVIS, Traumacel ENDO Applicator
Description: Haemostatic plant polysaccharide powder made of the oxidized cellulose with flexible applicator (38 cm).
Study: NCT05896384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon®
Description: Ethinylestradiol (EE) and Levonorgestrel (LNG)
Study: NCT05986643

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exergame+Neurofeedback
Description: Electroencephalography (EEG) is a device that measures the electrical activity of the brain (brain waves). There are several frequencies of brain waves when we are awake; alpha (medium), beta (fast), and theta (slow). Alpha frequencies of brain activity are linked to maintaining balance, with more alpha activity being associated with poorer balance. EEG neurofeedback treatment involves placing electrodes on a person's head to monitor and change brain activity by giving cued audio or visual feedback. It has been used in PwP to show improvements in balance and walking. Other preliminary research in PwP has shown that exercise can also improve balance.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exergame [alone]
Description: The exergame, delivered in virtual reality, involves travelling down a road (to give optic flow) whilst dodging balls that move towards the participant by either shifting their body either to the left or right. They are also be instructed to stand still and catch stars that appear and these will be used to score points and are associated with a monetary reward, ensuring motivation.~This group will receive SHAM feedback.
Study: NCT05618912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Description: A single hydrocolloid dressing will be applied to the surgical site for 7 days following dermatologic surgery
Study: NCT04694001

Intervention type: DEVICE
Group type: OTHER
Intervention: Use of the Atalante exoskeleton
Description: A session includes stand-up, walks, exercises with or without the assistance of the exoskeleton, rotation, side and back step, squat and sitting.
Study: NCT05618912

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Petrolatum jelly dressing
Description: The patient with the control wound will be covered with petrolatum jelly during this time period, which has to be re-applied daily.
Study: NCT06687655

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone-IQ
Description: This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This is the Ketone-IQ (1,3 Butanediol) intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone-IQ
Description: This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This is the Ketone-IQ (1,3 Butanediol) intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This is the Placebo intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This is the Placebo intervention.
Study: NCT06703229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The Transversus Abdominis Plane (TAP) block
Description: or injectate preparation, utilizing ultrasound guidance while the patient was supine. In the D1 group, patients were administered 20 mL of 0.25% isobaric bupivacaine with 0.5 mcg/kg of dexmedetomidine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The transverse abdominis plane (TAP) block
Description: Patients in the D2 group received 20 mL of 0.25% isobaric bupivacaine with 1 mcg/kg of dexmedetomidine.
Study: NCT06716021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The formulation of placebo will consist of water, sodium acetate, disodium EDTA, and sulfuric acid to reproduce the same pH as the etripamil formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil
Description: The formulation of etripamil is for IN administration and will consist of etripamil, water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg with an optional second dose of 70 mg 10 minutes after the first dose if symptoms persist.
Study: NCT06728631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candonilimab and ATRA
Description: Candonilimab at a dose of 6mg/kg IV Q3W will be administered until a maximum treatment duration of 1 year. All-trans retinoic acid will be administered at a dose of 25mg/m² twice daily on days 1-14, with a treatment cycle of 21 days, until a maximum treatment duration of 6 months, or until the occurrence of oral cancer or other malignancies, death, intolerable toxicity, withdrawal of informed consent, or any other reasons specified in the protocol.

Intervention type: OTHER
Group type: OTHER
Intervention: other treatment or observation
Description: other treatment other than Candonilimab/ATRA or observation
Study: NCT06727695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioStrength Intervention
Description: Participants in the Intervention Group will undergo BioStrength training using Technogym equipment. The intervention will last for 12 weeks, with sessions conducted 3 times per week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training
Description: Participants in the Active Comparator group will undergo a conventional strength training program using standard gym machines. Training sessions will occur 3 times per week for 12 weeks. The goal is to compare the outcomes of BioStrength training with traditional strength training.
Study: NCT06728891

Intervention type: OTHER
Intervention: In addition to routine diagnosis and treatment, no additional intervention measures were taken.
Description: This study does not impose any intervention on the patients
Study: NCT06729359

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography of the abdomen and pelvis
Description: ultrasonography of the abdomen and pelvis using a 3.5mhz abdominal probe

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography of the abdomen and pelvis
Description: ultrasonography of the abdomen and pelvis using a 3.5mhz abdominal probe
Study: NCT06332560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet (DI)
Description: 12-week personalized dietary advice based on the Dutch Dietary Guidelines under the guidance of a dietician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet (DI)
Description: 12-week personalized dietary advice based on the Dutch Dietary Guidelines under the guidance of a dietician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Seven individual sessions led by a psychotherapist. The content of the CBT will be psycho-education regarding pain mechanisms and DI.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Seven individual sessions led by a psychotherapist. The content of the CBT will be psycho-education regarding pain mechanisms and DI.
Study: NCT05478759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal affect recognition training
Description: 8 session, trains participants to recognize expression of emotion from a variety of stimuli, including dynamic stimuli (e.g., video instead of still pictures) and it employs both facial and vocal examples of emotion expression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training
Description: computerized attention drill training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brain Health Workshop
Description: an education presentation on brain function and cognitive principles of learning with homework and quizzes on information covered.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: National Geographic Movies
Description: participant will watch movies and answer questions after